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Background: Stentless aortic valve replacement (SAVR) became a common surgical procedure to treat aortic valve
disease, as it offers larger orifice area and improved hemodynamics. The aim of our single-centre retrospective
study was to assess long term results of first generation stentless aortic valves in young patients, where mechanical
prostheses are considered first line therapy.
Methods: From 1993 to 2001, 188 (149 male and 39 female) patients (≤60 years) underwent SAVR. Indications
were in 63.3% stenosis or mixed lesions and in 36.7% isolated regurgitation. Mean age of patients at surgery was
53.1 ± 7.1 years. Associated procedures were performed in 60 patients (31.9%). Follow-up data were acquired
through telephone interviews. Follow-up was 90.4% complete at a mean of 8.8 ± 4.7 years. Total follow-up was
1657.6 patient-years with a maximum of 17 years.
Results: Overall hospital mortality was 3.2% (2.5% for isolated SAVR). Overall actuarial survival-rate at 10/15 years
and freedom from reoperation at 10/14 years were 73.0% ± 3.5%/ 55.8% ± 5.4% and 81.0% ± 3.4%/ 58.0% ± 7.5%,
respectively. For isolated SAVR, actuarial survival at 10/15 years and freedom from reoperation at 10/14 years were
70.1% ± 4.4%/ 64.1% ± 4.8% and 83.1% ± 4.0%/ 52.9% ± 9.0%, respectively. Reoperation was performed in 42 patients
(22.3%) due to structural valve deterioration and endocarditis. Age (≤50 years) and associated procedures did not
significantly lower survival and freedom from reoperation, however, small prosthesis sizes (≤25 mm) did.
Conclusion: In patients aged 60 and younger, SAVR provides reliable long-term results especially for larger aortic valves.
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Stentless aortic valve replacement has become a com-
mon surgical treatment of aortic valve disease. These
prostheses are designed to allow physiological flow pat-
terns by avoiding an obstructive stent [1]. Various stud-
ies revealed controversial results comparing stented and
stentless prostheses. However, improved hemodynamics
and a larger orifice area could be shown in a recent
meta-analysis [2]. In a prospective randomized trial,
SAVR showed a midterm survival advantage compared
to stented aortic valve replacement (AVR) [3].
Implantation of bioprosthetic aortic valves is still con-
troversial in younger patients. The American Heart As-
sociation and the American College of Cardiology
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reproduction in any medium, provided the orthe age of 60 years, after lowering the age recommenda-
tion down from 65 years in 2010 [4]. Due to their ad-
vanced hemodynamics, SAVR might have a better
longevity and therefore may be used also in younger pa-
tients. The aim of our single-centre retrospective study
was to assess the first very long-term results of SAVRs
in patients ≤60 years.
Patients and methods
From 1993 to 2001, 839 patients underwent SAVR. After
excluding patients with endocarditis, dissection of the
ascending aorta and over the age of 60 years, 188 pa-
tients for this study were identified. Either the patient’s
explicit desire for bioprosthetic AVR or a contraindica-
tion to oral anticoagulation caused a decision for SAVR.
Mean age of patients at surgery was 53.1 ± 7.1 years.
Baseline preoperative characteristics are presented in
Table 1. Different types and sizes of prostheses used are
shown in Table 2. Isolated SAVR was performed in 120td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics
Characteristic Number Percent
Number of patients 188
Mean age 53.1 years
Mean standard error 7.1 years





> 50 years 145 77.1%
≤ 50 years 43 22.8%
Left ventricular function
Normal 109 58%
Moderately impaired 58 30.8%




Mixed lesion 57 30.3%
Timing of operation
Elective 185 98.4%
Urgent/ emergency 3 1.6%
Ascending aortic aneurysm 21 11.2%
Coronary artery disease 18 9.6%
Table 2 Operative data
Procedure Number Percent
Isolated SAVR 128 68.1%




CABG + other 5 2.6%
Myectomie 3 1.6%
Closure of VSD 1 0.5%
Passive Cardiomyoplasty* 1 0.5%
Surgical approach
Median sternotomy 182 96.8%
Upper ministernotomy 6 3.2%
Implanted valves
Edwards Prima-PlusW 120 63.8%
SJM Toronto-SPVW 50 26.6%
Medtronik FreeStyleW 10 5.3%
Vascutec ElanW 7 3.7%
Shelhigh-stentlessW 1 0.5%
Implanted valve sizes
23 mm 3 1.6%
25 mm 35 18.6%
27 mm 79 42.0%
29 mm 71 37.8%
AscAo = Replacement of ascending aorta; VSD = ventrical septal defect;
CABG= coronary artery bypass grafting; MVR =mitral valve repair/ replacement;
* = ACORNW Cardiac Support Device.
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patients (36.2%) and are presented together with opera-
tive data in Table 2.
Follow-up data were acquired through telephone in-
terviews. Follow-up was 90.4% complete at a mean of
8.8 ± 4.7 years. 21 patients were lost to follow-up. Total
follow-up was 1657.5 patient-years with a maximum of
17.0 years. Data collection and statistical analyses were
done according to the current guidelines for reporting
mortality and morbidity after cardiac valve interven-
tions [5]. The study was approved by the local Ethics
Committee (Ethikkommission der medizinischen Fakultät
der Charité - Universitätsmedizin Berlin).
Statistical analysis
All data were analyzed with PASW Statistics version
18.0.0 (SPSS Inc., Chicago, Illinois). Descriptive statistics
are reported as the mean ± standard deviation for con-
tinuous variables and as frequencies and percentages for
categorical variables, unless otherwise noted. Survival
and time-to-event analyses were performed using
Kaplan-Meier actuarial methods. Age-stratified curve
comparisons were performed using the log-rank test. All
p values were two-sided. In addition, proportional-hazard models were used to investigate the following
variables as risk factors for survival and freedom from
reoperation: gender, age, left ventricular ejection frac-
tion, aortic valve lesion, associated procedures, SAVR-
diameter. Left ventricular ejection fraction was assessed
by semi-quantitative definitions (normal, moderately im-
paired, profoundly impaired) due to bias because of the
long period of follow-up (involving various physicians
and different cardiovascular ultrasound systems). Statis-
tical significance was set at a p value of less than 0.05.
Preoperative only very few patients showed impaired
renal function, diabetes, and essential hypertension
(probably due to the low age of the patients) and conse-
quently these characteristics were not entered as covari-
ates in the analysis.
Age- and gender-matched survival estimates from the
general German population were obtained from the Hu-
man Lifetable Database [6]. Age- and gender-specific
conditional probabilities of surviving a 1-year age inter-
val were used to create an age- and gender-matched pa-
tient sample. The survival line depicted in the figure
comparing the general population with our study cohort
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Overall hospital mortality was 3.2% (n = 6). Causes for
hospital mortality were left ventricular failure (n = 3),
right ventricular failure (n = 1), electromechanical dis-
sociation (n = 1) and multi organ failure (n = 1). For iso-
lated SAVR hospital mortality was 2.5% (n = 3).
Patient survival
Overall actuarial survival at 10 and 15 years were 73.0% ±
3.5% and 55.8% ± 5.4%, respectively. For isolated SAVR
actuarial survival at 10 and 15 years were 70.1% ± 4.4%
and 64.1% ± 4.8%. During follow-up 61 patients died.
Linearized mortality rate is 3.6%/ year for overall SAVR
and 3.4%/year for isolated SAVR. Clinical follow-up of
the patients with the originally implanted valve still in
place showed only 1 patient in NYHA stadium III and
no patient in NYHA stadium IV.
Univariate statistical analyses revealed no significant sur-
vival difference between isolated SAVR and combined pro-
cedures. Neither patients aged ≥50 years and patients aged
<50 years, nor patients with isolated insufficiency as indica-
tion for operation and those with a stenotic valve lesion
showed a significant difference in comparison. Additionally
also the different models of SAVR did not influence survival.
Various other factors had a significant impact on survival
in univariate statistical analysis. Impaired left ventricularFigure 1 Survival after SAVR (Impact of left ventricular function and sfunction (left ventricular ejection fraction ≤ 50%) signifi-
cantly lowered survival. Patients with impaired left ven-
tricular function showed an actuarial survival-rate at 10
and 15 years of 61.2% ± 5.7%/ 40.6% ± 8.1% (Figure 1), re-
spectively. Besides this, patients with larger prosthesis sizes
(≥27 mm) compared with small prosthesis sizes (≤25 mm)
showed a significant survival benefit (Figure 1).
The multivariate proportional-hazard model supports
left ventricular function and prosthesis size to be inde-
pendent risk factors. Additional independent risk factors
were age and isolated insufficiency of the aortic valve.
(Table 3).
Freedom from reoperation
Reoperation was performed in 42 patients (22.3%).
Causes were structural valve deterioration (83.3%) and
endocarditis (16.7%). Structural valve deterioration
caused in most cases (85.7%) insufficiency and in 14.3%
stenosis.
Overall freedom from reoperation at 10 and 14 years
was 81.0% ± 3.4% and 58.0% ± 7.5%, respectively. For iso-
lated SAVR freedom from reoperation at 10 and 14 years
was 83.1% ± 4.0% and 52.9% ± 9.0%, respectively. Linear-
ized reoperation rate is 2.8%/year.
No significant statistical difference was found between
isolated SAVR and combined procedures. Additionally
also the different models of SAVR did not significantly
influence freedom from reoperation.
Noteworthy, in univariate statistical analysis only small
prosthesis size (≤25 mm) significantly lowered freedomize of SAVR).
Table 3 Risk factors for mortality and reoperation
Survival Freedom from Reoperation
Characteristic HR C I Significance HR C I Significance
Age (≤50) 2.55 1.13-5.75 0.02 0.98 0.45-2.11 0.96
Gender 1.21 0.57-2.64 0.61 1.95 0.84-4.53 0.12
Aortic valve lesion (stenosis vs. insufficiency) 0.55 0.31-0.95 0.03 0.74 0.35-1.57 0.44
Left ventricular function (normal vs. impaired) 0.39 0.22-0.68 0.01 1.08 0.55-2.15 0.05
Associated procedures 0.94 0.52-1.70 0.83 0.54 0.23-1.25 0.15
SAVR Diameter (≤25 mm vs. >25 mm) 2.15 1.13-4.09 0.02 3.53 1.57-7.92 0.02
CI = Confidence Interval, HR = Hazard ratio.
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lesion and combined procedures had no significant in-
fluence (Figure 2).
The multivariate proportional-hazard model also re-
vealed only prosthesis size as an independent risk factor
(Table 3).
Discussion
Nonrandomized and randomized clinical trials show evi-
dence that SAVR provides better hemodynamic perform-
ance than stented AVR [1,2,7]. This advantage could
reduce operative mortality, particularly in those with im-
paired left ventricular function. Late mortality could be
decreased by better left ventricular wall mass regression
and performance [2,8].
To compare this study to others is challenging. Most
other trials deal with cohorts of patients with far older
age. Besides this, our cohort showed a high percentageFigure 2 Freedom from Reoperation (Impact of prosthesis-diameter a(42%) of patients with impaired left ventricular function
(Table 1) with the inherent risk of premature death. Iso-
lated insufficiency as cause of AVR is well presented in
our cohort. Inferior early and long term survival has
been shown for those patients, especially in younger
age [9,10].
In 2010, McClure et al. published a late follow up after
implantation of Carpentier-Edwards pericardial AVR.
Overall actuarial survival at 10 and 15 years for patients
less than 65 years of age was 71.5% and 43.7% [11]. The
study population underwent more combined procedures
and had fewer patients with impaired left ventricular
function and insufficiency as cause of operation. Assum-
ing the cohort had the same mean age as ours (no mean
age was published) we see a more than 10% better sur-
vival rate after SAVR in our cohort.
Valfré et al. published a 25 year follow up of the
Hancock II porcine valve. Their patient cohort had lessnd patients age).
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Patients under 60 years showed a 10/15 year survival of
69.4/60.0% [12]. Because no mean age of study popula-
tion was given, one can only assume comparable long
term results.
Ruel et al. described a survival at 10 and 15 years of
82% and 70% in patients with a mean age of 47.6 years
[13]. They had fewer patients with impaired left ven-
tricular function and less combined procedures. With a
5.5 years older study cohort (in general population this
equals a decline in 15 year survival of around 8%) our
data suggest comparable long term results.
The only randomized prospective trial dealing with pa-
tients of almost the same mean age as ours, published
by Oxenham et al., compares Bjork-Shiley mechanical
valves with porcine AVR. A 10 year survival of 65.7% for
isolated AVR in this cohort is well below our survival
rate [14]. One has, however, to consider that those oper-
ations were performed in the 1970s.
Several randomized trials showed no significant survival
difference between mechanical AVR and bioprosthetic
AVR [14,15]. However, Ruel et al. showed a (nonsignifi-
cant) tendency of better survival towards bioprostheses of
around 13% at a 20 year follow-up and of around 10% at
25 year follow-up [13]. Above that, they also found a sig-
nificant difference in freedom from death after 20 years,
attributable to ischemic or hemorrhagic stroke, with
97.9 ± 1.2% in tissue AVR patients and 83.9 ± 4.9% in me-
chanical AVR patients [13]. Despite lifelong need for
anticoagulation treatment and elevated risk of bleeding
[14], the risk of thrombembolic complications ranges be-
tween 0.7%-3.0%, depending on valve type and other risk
factors [16].
The above mentioned problems in comparing different
study cohorts also compromise the comparison to age-
and gender-matched survival estimates from the German
general population. To create a comparable cohort, only
patients with isolated AVR and normal left ventricular
function were analyzed, whereas patients with isolated
aortic valve regurgitation as cause of operation were ex-
cluded because of the above mentioned impaired sur-
vival [9,10]. For the above described cohort a survival
rate comparable to the general population was seen
(Figure 3). One has to take into consideration that
reported mortality rates of younger patients after AVR
are higher than in the general population, while older
patients reach the same survival rate as the general
population [17].
Patients with impaired left ventricular function are es-
pecially demanding to compare. Survival in this cohort
is substantially reduced. At 14.43 ± 0.54 years (median
time of reoperation observed in this study), survival is at
40.6% ± 8.1%. After SAVR several authors reported a
greater improvement of left ventricular function [8] anda resulting survival benefit [18], so that SAVR should be
preferred in patients with impaired left ventricular
function.
Because small SAVRs (≤25 mm) were associated with
inferior survival in our study cohort, patient-prostheses
mismatch (PPM) has to be discussed in this context.
The concept of PPM was originally introduced by
Rahimtoola [19] and describes an effective prosthetic
valve area, which is smaller than that of a normal valve,
usually defined as effective valve orifice area indexed per
body surface (EOAI) smaller than 0.85 cm2/m2. PPM is
not to be expected in larger valve sizes. But smaller valve
sizes, especially stented bioprostheses smaller than
25 mm, can be associated with PPM. SAVRs usually fit
much more into patients native aortic root compared
with stented bioprostheses and offer larger orifice areas
due to their stentless construction. Therefore, PPM
should not occur in stentless bioprostheses and in a var-
iety of studies EOAI identified no mismatch [20]. Simi-
larly, no case of PPM could be identified in our cohort.
Nonetheless, small sizes of SAVRs were related to lower
survival. Potentially, there are other factors involved, e.g.
the higher reoperation rate in patients with small SAVR
could lower patients survival or there could be a direct
impact of the lower valve orifice area on survival. But
for such conclusion our study population (only 20.2% of
the patients received SAVRs ≤25 mm) is not large
enough and further studies are necessary.
Bioprosthetic AVR showed a time-dependent, decreased
longevity, caused by structural valve deterioration [3]. This
finally results in a rising need of reoperation. In 2006 the
American Heart Association and the American College of
Cardiology recommended the use of bioprosthetic aortic
valve replacements in patients above the age of 65 years
(depending on various other risk factors) [21]. An update
in 2010 lowered the age to 60 years [4]. Banbury et al.
showed that smaller sizes of bioprostheses have a ten-
dency to lower durability [22]. Due to larger orifice area
and less stress on the cusps of SAVR, their durability has
been expected to be better than stented AVR. Study re-
sults comparing SAVR and stented AVR are controversial
in terms of durability. Undoubtedly, the durability of the
prostheses decreases along with decreasing age of patients
[3]. Thus, the special dependence on the mean age of the
study cohort complicates the comparison of studies. Be-
sides this, most studies dealing with stented AVR only de-
scribe freedom from reoperation due to structural valve
deterioration. In case of SAVR, with the importance of the
surgical implantation itself for the function of the valve,
overall freedom from reoperation is much more relevant
in this study.
Welke et al. published a study on the Carpentier-
Edwards pericardial AVR, where 58% freedom from ex-
plantation after 10 years was given for patients of 21 to
Figure 3 Survival after SAVR compared to general population.
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of age [17]. For the same prostheses, age-stratified free-
dom from reoperation due to structural valve deterior-
ation after 14 years in patients ≤65 years of age was
around 35% [11]. After adding endocarditis and non-
structural valve deterioration this rate may even be worse.
For the Hancock II AVR, Valfré et al. described a free-
dom from reoperation rate of 62.6% in a small cohort of
patients ≤60 years (n = 50) at 15 years [12]. Rizzioli et al.
published a 15 year freedom from reoperation rate of
55.8% for patients ≤60 years [23]. However, in both pub-
lications no mean age for the cohort is given.
Ruel et al. described a median time to reoperation of
10.2 years after implantation of stented AVR in a patient
cohort with a mean age of 47.6 years [13]. Our patients
had a mean age of 53.1 ± 7.1 years and the median time
to reoperation was 14.43 ± 0.54 years.
Mechanical AVR showed lower reoperation rates. The
Veterans Affairs Randomized Trial, for example, reports
a reoperation-rate after mechanical AVR of 10% after
15 years [15]. However, this advantage is accompanied
by the above mentioned problems [13].
The pulmonary autograft procedure was introduced by
Ross in 1967 for young patients with aortic valve disease
[24]. The operation is connected with concerns regard-
ing late autograft competence and the consequences of
creating pulmonary valve disease. However, long term
results are promising [11,25]. Chambers et al. published
data for the pulmonary autograft procedure. They
reported a survival rate of the hospital survivors of 61%,
freedom from autograft replacement of 75%, andfreedom from replacement of pulmonary position homo-
grafts of 80% 20 years after operation [11]. However, one
has to keep in mind that the mean age in this cohort
was 32 years and the procedures were done between
1967 and 1984.
In recent years a rapid progression of percutaneous AVR
can be seen. In Germany, 23.9% of isolated AVR was
performed catheter-based in 2010 [26]. If long-term results
are promising and this development persists we can as-
sume that various reoperations can be performed catheter-
based. This, however, is only possible after biological AVR.
Limitations
The retrospective nature of this study design can lead to
an underestimation of complication rates (endocarditis,
thrombembolic events and bleeding etc.). Because it is
likely that some events would not be captured, either be-
cause of patients´ misinterpretation of our questions or
recall bias, some data were not surveyed. Also, NYHA
functional class is subjective. Underestimation of symp-
tom severity may lead to overestimation of potential
clinical benefit in the statistical analysis. That is why
these data were not analyzed. The different types of
SAVR used in the researched cohort and pooling of the
clinical results may have influenced the valve-related
outcomes, even though the type of SAVR did not appear
to be of statistical relevance.
Despite these limitations one has to consider the fact
that a controlled randomized trial in young patients in-
volving stentless, stented and mechanical AVR is ethic-
ally very difficult to perform, if not impossible.
Christ et al. Journal of Cardiothoracic Surgery 2013, 8:68 Page 7 of 7
http://www.cardiothoracicsurgery.org/content/8/1/68Conclusion
In respect of the mentioned limitations of the study and
the comparison to other publications (to our knowledge
no research for larger cohorts of patients ≤ 60 years with
SAVR is published), our data show long-term results in
survival which are comparable or even better than stented
AVR and mechanical AVR. Freedom from reoperation is at
least comparable to stented AVR. Mechanical AVRs show
higher freedom from reoperation, but the risk of
reoperation has to be weighed against the risk of lifelong
anticoagulation treatment and stroke. In respect of the re-
cent and rapid development in the field of catheter-based
AVR, one should also be aware that after mechanical AVR,
patients are deprived of this therapeutic option. Compari-
son of SAVR to the pulmonary autograft procedure in
terms of survival is limited due to different mean age of
study populations. In terms of freedom from reoperation,
the pulmonary autograft procedure is superior.
We conclude that SAVR is a good and safe alternative
to mechanical prostheses in patients aged ≤ 60 years and
should be considered preferably in patients with im-
paired left ventricular function.
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